STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Profusa, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Profusa, Inc. (PFSA) received an amended Schedule 13G from a group led by Ascent Partners Fund LLC reporting beneficial ownership of 4,005,419 shares, representing 9.99% of the common stock as of September 30, 2025.

The filing notes a 9.99% beneficial ownership limitation in related instruments, including convertible notes, a warrant dated July 20, 2025, and an ELOC Agreement dated July 28, 2025, which cap conversions, exercises, and purchases. Ascent held 900,000 shares directly as of September 30, 2025. Ownership percentages reference 36,088,877 shares outstanding per a Form S-1, plus 900,000 shares from a warrant exercise, for a total of 36,988,877 shares outstanding.

The group certifies the securities were not acquired to change or influence control. Voting and dispositive powers are reported as shared for 4,005,419 shares and none sole.

Positive
  • None.
Negative
  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of common stock, par value $0.0001 per share, of the issuer (the "Common Stock") set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount (as defined in this footnote), the shares of Common Stock to be issued upon (x) conversions of convertible promissory notes (the "Convertible Notes"), effective July 11, 2025 and December 29, 2023 respectively, held directly by the reporting person (y) exercises of a certain common stock purchase warrant of the issuer, dated July 20, 2025, held directly by the reporting person (the "Warrant") and (z) purchases by the reporting person pursuant to that certain Securities Purchase Agreement, dated as of July 28, 2025, between the issuer and the reporting person (the "ELOC Agreement") whereby, subject to certain conditions, the issuer may, at its option but subject to the Blocker Amount, require the reporting person to purchase Common Stock. The Note, Warrant and ELOC Agreement are all subject to a maximum 9.99% beneficial ownership limitation contained therein (the "Blocker Amount"). In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Report on Form S-1 filed with the U.S. Securities and Exchange Commission on August 29, 2025 (the "Form S-1"), plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of Common Stock set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount, the shares of Common Stock to be held indirectly by the reporting person upon (x) conversions of the Convertible Notes, (y) exercises of the Warrant and (z) purchases pursuant to the ELOC Agreement. The Notes, Warrants and ELOC Agreement are all, in the aggregate, limited by the Blocker Amount. In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Form S-1, plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of Common Stock set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount, the shares of Common Stock to be held indirectly by the reporting person upon (x) conversions of the Convertible Notes, (y) exercises of the Warrant and (z) purchases pursuant to the ELOC Agreement. The Notes, Warrants and ELOC Agreement are all, in the aggregate, limited by the Blocker Amount. In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Form S-1, plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of Common Stock set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount, the shares of Common Stock to be held indirectly by the reporting person upon (x) conversions of the Convertible Notes, (y) exercises of the Warrant and (z) purchases pursuant to the ELOC Agreement. The Notes, Warrants and ELOC Agreement are all, in the aggregate, limited by the Blocker Amount. In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Form S-1, plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of Common Stock set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount, the shares of Common Stock to be held indirectly by the reporting person upon (x) conversions of the Convertible Notes, (y) exercises of the Warrant and (z) purchases pursuant to the ELOC Agreement. The Notes, Warrants and ELOC Agreement are all, in the aggregate, limited by the Blocker Amount. In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Form S-1, plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of Common Stock set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount, the shares of Common Stock to be held indirectly by the reporting person upon (x) conversions of the Convertible Notes, (y) exercises of the Warrant and (z) purchases pursuant to the ELOC Agreement. The Notes, Warrants and ELOC Agreement are all, in the aggregate, limited by the Blocker Amount. In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Form S-1, plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of Common Stock set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount, the shares of Common Stock to be held indirectly by the reporting person upon (x) conversions of the Convertible Notes, (y) exercises of the Warrant and (z) purchases pursuant to the ELOC Agreement. The Notes, Warrants and ELOC Agreement are all, in the aggregate, limited by the Blocker Amount. In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Form S-1, plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of Common Stock set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount, the shares of Common Stock to be held indirectly by the reporting person upon (x) conversions of the Convertible Notes, (y) exercises of the Warrant and (z) purchases pursuant to the ELOC Agreement. The Notes, Warrants and ELOC Agreement are all, in the aggregate, limited by the Blocker Amount. In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Form S-1, plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth on row (11) above and the number of shares of Common Stock set forth on rows (6), (8) and (9) above includes, up to the Blocker Amount, the shares of Common Stock to be held indirectly by the reporting person upon (x) conversions of the Convertible Notes, (y) exercises of the Warrant and (z) purchases pursuant to the ELOC Agreement. The Notes, Warrants and ELOC Agreement are all, in the aggregate, limited by the Blocker Amount. In Row (11) the percentage is based on (i) 36,088,877 shares of Common Stock outstanding, as reported by the issuer in its Form S-1, plus 900,000 shares of Common Stock received by Ascent as part of the Warrant exercise, for a total 36,988,877 shares outstanding, and (ii) shares of Common Stock issued upon partial conversion of the Convertible Note, and the purchase of some Common Stock pursuant to the ELOC Agreement, in each case subject to the Blocker Amount.


SCHEDULE 13G



Ascent Partners Fund LLC
Signature:/s/ Ascent Partners Fund LLC
Name/Title:Mikhail Gurevich, signatory for Managing Member of Managing Member
Date:11/13/2025
Ascent Partners LLC
Signature:/s/ Ascent Partners LLC
Name/Title:Mikhail Gurevich, signatory for Managing Member
Date:11/13/2025
Dominion Capital LLC
Signature:/s/ Dominion Capital LLC
Name/Title:Mikhail Gurevich, Managing Member of Dominion Capital Holdings LLC, Manager of Dominion Capital GP LLC, Manager of Dominion Capital LLC
Date:11/13/2025
Dominion Capital GP LLC
Signature:/s/ Dominion Capital GP LLC
Name/Title:Mikhail Gurevich, Managing Member of Dominion Capital Holdings LLC, Manager of Dominion Capital GP LLC
Date:11/13/2025
Dominion Capital Holdings LLC
Signature:/s/ Dominion Capital Holdings LLC
Name/Title:Mikhail Gurevich, Managing Member
Date:11/13/2025
Masada Group Holdings LLC
Signature:/s/ Masada Group Holdings LLC
Name/Title:Alon Brenner, Managing Member
Date:11/13/2025
Mikhail Gurevich
Signature:/s/ Mikhail Gurevich
Name/Title:Mikhail Gurevich
Date:11/13/2025
Gennadiy Gurevich
Signature:/s/ Gennadiy Gurevich
Name/Title:Gennadiy Gurevich
Date:11/13/2025
Alon Brenner
Signature:/s/ Alon Brenner
Name/Title:Alon Brenner
Date:11/13/2025
Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

What ownership stake is reported in Profusa (PFSA)?

9.99% beneficial ownership, covering 4,005,419 shares of common stock as of September 30, 2025.

Who are the reporting persons in PFSA’s Schedule 13G/A?

Ascent Partners Fund LLC and affiliated entities/persons, including Ascent Partners LLC, Dominion Capital entities, Masada Group Holdings LLC, Mikhail Gurevich, Gennadiy Gurevich, and Alon Brenner.

What limits further increases in PFSA ownership?

A 9.99% beneficial ownership limitation in the convertible notes, warrant, and ELOC Agreement caps conversions, exercises, and purchases.

How many PFSA shares were outstanding for the calculation?

The percentage references 36,088,877 shares outstanding per a Form S-1, plus 900,000 from a warrant exercise, totaling 36,988,877.

How many PFSA shares are held directly by Ascent?

As of September 30, 2025, Ascent held 900,000 shares directly.

Does the filing seek to influence control of Profusa?

No. The group certified the securities were not acquired to change or influence control.

What are the voting and dispositive powers reported?

Sole voting/dispositive power: 0. Shared voting/dispositive power: 4,005,419 shares.
Profusa Inc

NASDAQ:PFSA

PFSA Rankings

PFSA Latest News

PFSA Latest SEC Filings

PFSA Stock Data

7.06M
29.51M
37.1%
0.38%
4.53%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK